Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, ...
High-dose vitamin D added to chemotherapy failed to provide a benefit in patients with metastatic colorectal cancer in the ...
Amgen (NASDAQ: AMGN) today announced the presentation of new data across its broad oncology pipeline and portfolio at the ...
Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...
Amgen and Allergan's biosimilar of Roche ... While the US patent on Avastin (bevacizumab) expires in 2019, the drug’s main European patent expires in 2022. Nevertheless the approval of the ...
Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...
Medpage Today on MSN2d
Rucaparib-Nivolumab Maintenance Not the Answer in Newly Diagnosed Ovarian CancerAdding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly ...
The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone ...
The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback